BREXAFEMME® (ibrexafungerp)
Vulvovaginal Candidiasis (VVC) and Recurrent VVC (rVVC)
ApprovedMarketed; Partnered with GSK
Key Facts
Indication
Vulvovaginal Candidiasis (VVC) and Recurrent VVC (rVVC)
Phase
Approved
Status
Marketed; Partnered with GSK
Company
About Scynexis
Scynexis is committed to protecting the world against dangerous and difficult-to-treat fungal pathogens, a mission driven by its innovative 'fungerp' platform. The company achieved a significant milestone with the FDA approval and subsequent partnership with GSK for BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis. Its strategic focus now includes advancing its second-generation fungerp, SCY-247, through clinical development for serious invasive infections, addressing the critical global threat of antimicrobial resistance.
View full company profile